Dr. Shen brings more than 20 years of pharmaceutical experience with a focus on drug development for cancer, genetic diseases and rare diseases. Before founding AceLink in 2019, he was Executive Director at BioMarin Pharmaceutical reporting to Chief Scientific Officer Leonard Post, and led drug discovery projects for several rare genetic diseases.  Before joining BioMarin, he was VP of Biology at LEAD Therapeutics where he led all aspects of biology for several drug discovery projects, including discovery of the PARP inhibitor talazoparib.  LEAD Therapeutics was acquired by BioMarin in 2010 and he joined BioMarin as a part of the acquisition.  Before LEAD Therapeutics, he served as VP of R&D at Applied Biomics, a protein biomarker research and service company that he co-founded in 2003. Prior to that, he worked at Onyx Pharmaceuticals, where he served at positions with increasing responsibilities and helped development of oncolytic viruses and gene delivery viral vectors.

Dr. Shen holds B.S. in Physiology from Fudan University, PhD in Molecular Biology from State University of New York at Buffalo, and received post-doctoral training in Dr. Thomas Shenk’s lab at Princeton University. He has co-authored more than 35 peer-reviewed papers and is a co-inventor in more than 30 issued and pending patents. In 2018, talazoparib, a cancer drug for which he led the biology aspects until Phase 3 clinical trials at LEAD and BioMarin, received marketing approval from FDA.